stockrow
Saturday 7 November 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
- EPS
- +55.1%
- Free cash flow
- −65.0%
- Total debt
- −88.4%
Quarter to June 2026, against a year earlier
6.09
0.42
+7.41%
Follow PYPD
Alert me
PolyPid Ltd. (PYPD) P/E ratio
PolyPid Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| CHRS Coherus Oncology, Inc. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| PYPD PolyPid Ltd. | n/m |
| CDXS Codexis, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)